Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The big hope is that Europe will move faster to implement reforms in the face of competitive threats from the US ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best falling ...

US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk's anti-TFPI antibody concizumab has ... including Japan, Australia, and Switzerland, but was rejected by the FDA last year with a request for more information related to the ...

European markets have received a positive lead-in from Wall Street, where the benchmark S&P 500 index hit a record high after President Donald Trump, speaking online at the World Economic Forum in ...